dcr disease control rate clinicaltrials.gov

Keyword	CPC	PCC	Volume	Score	Length of keyword
dcr disease control rate clinicaltrials.gov	1.74	0.9	1241	91	43
dcr	0.23	0.3	3882	50	3
disease	0.47	0.2	616	14	7
control	0.69	0.8	5473	37	7
rate	0.13	0.1	7384	73	4
clinicaltrials.gov	0.38	0.4	5609	39	18

Keyword	CPC	PCC	Volume	Score
disease control rate dcr	0.89	0.3	8690	3
dcr in clinical trials	0.02	0.1	5599	37
derived count rate dcr	0.49	0.1	6806	92
clinical benefit rate vs disease control rate	1.69	0.2	5793	80
department of clinical research dcr	0.28	0.8	8303	71
cdr in clinical trials	0.15	0.1	3506	97
ecrin clinical trials	1.1	0.1	8718	6
what is dcr in clinical trials	0.78	0.9	1303	57
cr in clinical trials	1.07	0.5	4829	77
what is dcr in cancer	1.46	0.2	1049	7
what is a dcr procedure	0.54	0.9	9641	100
dcr meaning in ophthalmology	0.24	0.5	7988	49
what is dcr in medical terms	1.96	0.5	5668	99
what is dcr medical	1.24	0.5	9565	81
tcr-t clinical trials	0.05	0.2	2783	7
clinical trials washington dc	1.07	0.5	8631	100
what is a dcr in mental health	1.32	0.2	1031	39
adr in clinical trials	1.98	0.8	5302	81
what is the dcr	1.96	0.8	4674	47
crc in clinical trial	0.98	0.9	1930	56
rcr clinical research meaning	1.77	0.4	6931	26
what is a dcr report	1.74	0.9	3400	51
what is a dcr evaluation	0.35	0.3	6135	53
dcr stands for medical term	1.18	0.8	6007	98
what is dcr surgery	1.94	0.2	6981	7
dcr/ecr	0.36	1	28	6
dcr/acr	0.17	0.1	375	75
disease control rate definition	1.31	0.6	604	35
disease control rate deutsch	0.16	0.6	8885	94
disease control rate definition oncology	1.3	0.5	6753	52
what is disease control rate	0.68	0.7	7666	35
disease control rate oncology	1.99	0.9	5639	64
dcr dark count rate	1.17	0.7	8980	51

Search Results related to dcr disease control rate clinicaltrials.gov on Search Engine

Reporting disease control rates or clinical benefit rates in early
nih.gov

https://pubmed.ncbi.nlm.nih.gov/21268434/

DA: 89 PA: 16 MOZ Rank: 17

Reporting disease control rates or clinical benefit rates in early
nih.gov

https://pubmed.ncbi.nlm.nih.gov/21268434/

DA: 83 PA: 89 MOZ Rank: 96

Bicalutamide and Abemaciclib in Inoperable or Metastatic …
clinicaltrials.gov

https://classic.clinicaltrials.gov/ct2/show/NCT06365788

WebApr 15, 2024 · Disease control rate (DCR) at 24 weeks for treatment with abemaciclib in combination with bicalutamide in all patients, in the 4 cohorts separate and in the …

DA: 41 PA: 57 MOZ Rank: 83

Clinical endpoints in oncology - a primer - PMC - National Center …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085844/

WebApr 15, 2021 · Disease control rate (DCR) describes the percentage of patients with advanced cancer whose therapeutic intervention has led to a complete response, … Author: Amanda Delgado, Achuta Kumar Guddati Publication: Am J Cancer Res. 2021; 11(4): 1121-1131. Publish Year: 2021 Published: 2021

Author: Amanda Delgado, Achuta Kumar Guddati
Publication: Am J Cancer Res. 2021; 11(4): 1121-1131.
Publish Year: 2021
Published: 2021

DA: 83 PA: 20 MOZ Rank: 32

Study of Single Agent Pembrolizumab (MK-3475) Versus Single …
clinicaltrials.gov

https://classic.clinicaltrials.gov/ct2/show/NCT02555657

WebSep 21, 2015 · Disease Control Rate (DCR), based on BICR assessment per RECIST 1.1, was defined as the percentage of participants who had a Complete Response (CR: … Actual Enrollment : 622 participants Intervention Model: Parallel Assignment Allocation: Randomized Study Type : Interventional (Clinical Trial)

Actual Enrollment : 622 participants
Intervention Model: Parallel Assignment
Allocation: Randomized
Study Type : Interventional (Clinical Trial)

DA: 43 PA: 4 MOZ Rank: 31

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel …
clinicaltrials.gov

https://classic.clinicaltrials.gov/ct2/show/NCT03981796

WebJun 11, 2019 · A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced … Actual Enrollment : 787 participants Intervention Model: Parallel Assignment Allocation: Randomized Study Type : Interventional (Clinical Trial)

Actual Enrollment : 787 participants
Intervention Model: Parallel Assignment
Allocation: Randomized
Study Type : Interventional (Clinical Trial)

DA: 98 PA: 3 MOZ Rank: 78

Disease control rate at 8 weeks predicts subsequent survival in
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789142/

WebIn the present study, we hypothesized that DCR at 8-weeks would be a superior predictor of clinical benefit than tumor response rate in patients with ES-SCLC receiving … Author: Primo N. Lara, James Moon, Mary W. Redman, Thomas J. Semrad, Karen Kelly, Jeffrey Allen, Barbara Git... DOI: 10.1016/j.cllc.2015.09.003 Publish Year: 2016 Published: 2016/03

Author: Primo N. Lara, James Moon, Mary W. Redman, Thomas J. Semrad, Karen Kelly, Jeffrey Allen, Barbara Git...
DOI: 10.1016/j.cllc.2015.09.003
Publish Year: 2016
Published: 2016/03

DA: 64 PA: 17 MOZ Rank: 39

Reporting disease control rates or clinical benefit rates in early
nih.gov

https://pubmed.ncbi.nlm.nih.gov/21268434/

WebDisease Control Rate (DCR) and Clinical Benefit Rate (CBR) are defined as the percentage of patients with advanced or metastatic cancer who have achieved complete …

DA: 17 PA: 21 MOZ Rank: 36

Disease control and objective responsive rates in randomized …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182707/

WebOct 16, 2020 · Instead of objective response rate, disease control rate should be used as the primary endpoint in a randomized phase II trial evaluating non-first-line …

DA: 34 PA: 23 MOZ Rank: 28

Final results of DESTINY-CRC01 investigating trastuzumab
nature.com

https://www.nature.com/articles/s41467-023-38032-4

WebJun 7, 2023 · Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of …

DA: 32 PA: 3 MOZ Rank: 55